Clearmind CMND-100 Shows Positive Safety in FDA Clinical Trial Part A

Key Highlights

• Clearmind announced positive safety findings for CMND-100 in Part A of its FDA-regulated Phase I/II clinical trial.
• CMND-100 is a proprietary MEAI-based oral drug candidate for Alcohol Use Disorder (AUD), addictions, and weight management.
• All 24 participants across four ascending-dose cohorts successfully completed treatment.
• The study achieved its primary endpoint of safety and tolerability, with a consistent safety profile.
• No serious adverse events were observed, and tolerability remained strong up to the highest dose of 160 mg.
• The company plans to advance to subsequent stages of the clinical program, including dosing AUD patients.